Agoracom Blog

FEATURE: 7km’s of Gold Vault Strike Between 3 Gold Producers $OPW.ca

Posted by AGORACOM-JC at 4:34 PM on Monday, July 17th, 2017

Opw

WHY OPAWICA?

  • 7km’s of gold vault strike between 3 gold producers
  • In one of the largest gold producing regions in Canada
  • Adjoining to Ridgemont, Granada and Kinross Gold Producing Mines in Rouyn-Noranda Quebec
  • Bazooka properties cover 7 kilometres of the prolific CLLB
  • Cadilac-lardner lake fault system has produced Over 200M oz of GOLD

BAZOOKA EAST GOLD PROPERTY ‐ QUEBEC

Phase I drilling program consisted of five holes totalling 2,172 metres of drilling.

  • Hole 01 intersected a wide zone of gold mineralization approximately 185 metres east of a Lake Shore Gold Corp. (“LSG”) hole drilled in 2004 (BA-03-02A), which returned several narrow high grade gold intercepts with visible gold along with intermittent anomalous gold values.
  • In addition, drilling completed in 2011 by RT Minerals Corp. (“RTM”) intersected this favourable horizon (zone) about 50 metres east of current Opawica drilling. This historic hole intersected 17 metres of core length at 7.86 g/t Au (RTM June 21, 2011 press release).
  • With the 54.8 metre wide zone intersected in current drilling a further review of the historic LSG hole has resulted in the restating of the LSG hole at 1.68 g/t Au (uncut) (including 17 metres at 3.59 g/t Au) and 0.95 g/t (cut to 31 g/t Au) over 48 metres. The current Opawica hole and the historic LSG hole both contained fuchsite and arsenopyrite and are in close proximity to the Cadillac Larder Lake Break (“CLLB”).
  • Hole 02 in the current program intersected highly anomalous gold values (0.17 g/t Au) over the same zone for 39.9 metres. Hole 03 also intersected the same zone returning anomalous gold values (0.12 g/t Au) over 20.5 metres. Hole 04 also hit the same zone returning anomalous gold values and Hole 05 intersected the zone over a width of 65.5 metres containing highly anomalous gold values (0.24 g/t Au).

All of the above current and historic intervals are estimated at approximately 85% to 95% true widths. Assaying was completed by Swastika Laboratories Ltd. of Kirkland Lake, Ontario.An NI 43-101 technical report on the Bazooka property dated March 20, 2016

HISTORICAL RESULTS

BAZOOKA PROPERTY – EAST BOUNDARY

MCWATTERS GOLD PROPERTY

  • Bazooka and McWatters gold properties are located near Rouyn Noranda, Quebec, and are situated along the prolific Cadillac
    -Larder Lake Break (“CLLB”)
  • Company owns 100% interest in the Bazooka & McWatters properties Adjacent Bazooka and Bazooka West properties extend the Company’s strike length along the CLLB to approximately 7 km.
  • Kinross has signed a CDN $60 million definitive option agreementto purchase 100% of the adjacent Yorbeau Resources Inc. Rouyn Property (see Yorbeaupress release of October 25, 2016).

FACT SHEET

CORPORATE PRESENTATION

12 MONTH STOCK CHART

PyroGenesis Announces Receipt of CAN$445,950 Under Existing Military Contract; Plus CAN$300,000 of Warrants exercised $PYR.ca

Posted by AGORACOM-JC at 9:02 AM on Monday, July 17th, 2017

Pyr header 1

  • Further to its press release of January 10, 2017, wherein it was announced that the Company had signed two additional military contracts totaling approx. US$1.2MM (CAN$1.6MM)
  • Company has received US$367,982 (CAN$445,950) under one of these contracts.

MONTREAL, QUEBEC–(July 17, 2017) – PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX VENTURE:PYR)(OTCQB:PYRNF), a high tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma based systems and plasma torch products, is pleased to announce today that, further to its press release of January 10, 2017, wherein it was announced that the Company had signed two additional military contracts totaling approx. US$1.2MM (CAN$1.6MM), the Company has received US$367,982 (CAN$445,950) under one of these contracts.

The payment announced today is one of several payments received since January 10, 2017, by PyroGenesis totaling US$925,122 (CAN$1.2MM) under an original contract worth US$978,312 (CAN$1.25MM). The balance of approximately US$53K (CAN$68K) is expected to be received during Q3 2017.

Additionally, the Company announces today that CAN$300,000 of warrants have been exercised. “This exercise of warrants is timely,” said P. Peter Pascali, President and CEO of PyroGenesis. “We are currently looking beyond the ramp-up phase towards increasing production capacity ahead of our original expectations. This exercise of warrants, together with any future exercise of warrants and options, will enable us to implement plans to accelerate our original schedule to increase our production capacity of metal powders for the Additive manufacturing (3D Printing) industry. We are currently looking at ways to have up to three (3) additional powder production systems operating in 2018. Overall, to date, our metal powder production strategy is progressing far better than planned, and we are very pleased.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc. is the world leader in the design, development, manufacture and commercialization of advanced plasma processes. PyroGenesis provides engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Its core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Its operations are ISO 9001:2008 certified, and have been ISO certified since 1997. PyroGenesis is a publicly-traded Canadian company on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace (Ticker Symbol: PYRNF). For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

Rodayna Kafal
VP, Investor Relations and Communications
(514) 937-0002
ir@pyrogenesis.com or rkafal@pyrogenesis.com
www.pyrogenesis.com

BOOOM! Patriots, Mets Amongst Pro Teams That Bought Cities In Overwatch Global ESports League. $GMBL.us

Posted by AGORACOM-JC at 3:33 PM on Wednesday, July 12th, 2017
  • Blizzard has announced major investment in its Overwatch League, the official home of Overwatch esports, first announced at last year’s Blizzcon.
  • Seven team slots have been acquired by organisations from both the traditional sports and esports worlds, as well as a couple of tech-focused entrepreneurs, with ESPN reporting a potential fee of $20 million per team.

“We’re not commenting on the price of the spot,” said Nate Nanzer, Commissioner of the Overwatch League when I spoke to him this week. “But we can talk a little bit about the terms of the relationship.

“I think one of the key differences in our structure is the local opportunity. There really hasn’t been a city-based, global league in this way. Not just in esports, but in traditional sports too, there hasn’t ever really been a league where Los Angeles plays Shanghai in the regular season.”

When a team owner purchases a position in the league, they also acquire the rights to a city of their choice. Boston, for example, has been picked up by Robert Kraft, the Chairman and CEO of the American football team, the New England Patriots.

His team will eventually have a home stadium in Boston, with all local revenues (up to an undisclosed figure) remaining with the team itself. On top of that, the team will have the option to host and monetise up to five amateur Overwatch League events in their home territory each year.

The other team owners include Jeff Wilpon, the COO of the New York Mets, who unsurprisingly nabbed New York as his team’s city of choice, as well as a couple of tech organisations based out of Shanghai and Seoul. There are also three esports-only teams, often referred to as ‘endemics’: Immortals (Los Angeles), Misfits Gaming (Miami-Orlando) and NRG Esports (San Francisco).

“I’m happy to announce that we have three endemic teams to reveal today, despite the fact that the internet says we don’t talk to endemics,” said Nanzer. “Obviously we’re also very excited about the traditional sports owners because they bring a lot of incredible history to the table: building generational fandom around their teams and great local expertise, which is important for our city-based, home and away structure.”

ow_league_2

The Commissioner.

A couple of weeks ago, Eurogamer published an article that questioned the current state of Overwatch esports, suggesting that since the announcement of the Overwatch League in November, very little has actually happened. More than that, its announcement in some ways had a damaging effect on the tournaments operating outside of the league itself.

“We wanted to make sure that when we spoke with our community next in a meaningful way, we had really important stuff to talk about,” said Nanzer when I questioned him on this. “Building a sports league from scratch is pretty hard and takes a lot of time.

“Blizzcon is obviously the best place ever for us to announce anything, but do I wish Blizzcon had been in March or April, instead of November? Sure.”

We’re still waiting on the league’s official start date, although we’ve been been told the first season will begin at some point this year. For the duration of that season, all matches will be played at a venue in Los Angeles, giving the seven team owners time to build up the necessary local infrastructure they’ll require going forwards.

During the league itself, matches will be played every Thursday, Friday and Saturday and we can apparently expect the match schedule soon™.

Source: http://www.eurogamer.net/articles/2017-07-12-blizzards-big-plan-for-overwatch-esports-allows-teams-to-buy-cities

Tetra Bio-Pharma Announces Results of Voting at Annual Shareholders’ Meeting & Provides a Corporate Update $TBP.ca

Posted by AGORACOM-JC at 5:30 PM on Tuesday, July 11th, 2017

Tbp large new

  • Tetra is the only pharmaceutical company to have clinical studies for smoked marijuana;
  • The Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001. Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline

OTTAWA, ONTARIO–(July 11, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), is pleased to announce the results of the vote at its July 10, 2017 annual shareholders’ meeting.

Resolution For Against Withheld Spoiled No Vote % For % Against % Withheld
André Rancourt 18,439,319 0 19,449 0 443,314 99.89 % 0.00 % 0.11 %
André D. Audet 18,439,304 0 19,464 0 443,314 99.89 % 0.00 % 0.11 %
Robert Brouillette 18,456,735 0 2,033 0 443,314 99.99 % 0.00 % 0.01 %
Dr. W.M. (Bill) Cheliak 18,456,750 0 2,018 0 443,314 99.99 % 0.00 % 0.01 %
Appointment of McGovern, Hurley, Cunningham, LLP, as auditors of the Corporation and to authorize the directors to fix the remuneration to be paid to the auditors. 18,884,340 0 17,742 0 0 99.91 % 0.00 % 0.09 %
The amendment of the Stock Option Plan from fixed to rolling. 18,282,545 176,222 0 0 443,315 99.05 % 0.95 % 0.00 %

At the meeting, some key corporate highlights which were discussed, included:

  • Tetra is the only pharmaceutical company to have clinical studies for smoked marijuana;
  • The Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001. Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • The initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than what we expected for sales. We are now putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control. We will look at launching PPP001 using the ACMPR license by the end of summer. See press release announced April 17, 2017 for further information;
  • We are looking to start the Phase II clinical trials for PPP002 – Dronabinol XL in the next month; and
  • Investor outreach will be principally focused on the U.S. market going forward looking at targeting healthcare funds to potentially invest in Tetra. Communications strategy is to make very clear that Tetra is not a marijuana company but a pharmaceutical company.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

PyroGenesis Announces Receipt of $230,168 Contract for Support During Testing of its Chemical Warfare Agent Destruction System Using Real Chemical Warfare Agents $PYR.ca

Posted by AGORACOM-JC at 8:46 AM on Tuesday, July 11th, 2017

Pyr header 1

  • Received a CAN$230,168 contract to provide technical support during the next and final testing phase of its tactical Plasma Arc Chemical Warfare Agents Destruction System
  • Will now be tested using real chemical warfare agents

MONTREAL, QUEBEC–(July 11, 2017) – PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX VENTURE:PYR)(OTCQB:PYRNF), a high tech company (the “Company” or “PyroGenesis” or “PCI”) that designs, develops, manufactures and commercializes plasma based systems and plasma torch products, is pleased to announce today that, further to its press release of April 19, 2017, it has received a CAN$230,168 contract to provide technical support during the next and final testing phase (the “Final Testing Phase”) of its tactical Plasma Arc Chemical Warfare Agents Destruction System (“PACWADS” or the “System”) which will now be tested using real chemical warfare agents.

On April 19, 2017, the Company announced that it had, in coordination with the US-based Southwest Research Institute (SwRI), successfully completed long-duration performance tests using the Company’s System with surrogate chemical warfare agent material. These tests supported the Defense Advanced Research Projects Agency (DARPA) Agnostic Compact Demilitarization of Chemical Agents (ACDC) program and the results far exceeded minimum requirements with over 99.9999% destruction efficiency. The Final Testing Phase, which is expected to take approximately six (6) months, will be conducted using real chemical warfare agents at secure military facilities abroad, and is expected to confirm the results obtained at PyroGenesis’ facilities using surrogate chemical warfare agents.

“We are highly confident that our System will pass the Final Testing Phase particularly given the fact that we significantly exceeded the minimum requirements of 99.99% destruction efficiency using surrogates,” said Pierre Carabin, Chief Technology Officer of PyroGenesis. “As previously announced, our System demonstrated more than 99.9999% efficiency using surrogates which emulated destruction of such chemical warfare agents such as sarin (GB), soman (GD), and mustard (HD). This additional contract will allow PyroGenesis to support testing using real chemical warfare agents at a secure site.”

The System has already been shipped to a secure site and the Final Testing Phase begun. These tests are expected to be completed by the end of Q3 2017; however, this timeline is out of the Company’s control.

“If successful, PACWADS will be one of the few technologies in the world capable of destroying chemical warfare agents. We anticipate that such success will open the doors to additional opportunities; for example, the safe destruction of Ebola contaminated material in countries such as Liberia”, said Philippe Beaulieu, Senior Project Manager at PyroGenesis.

“A successfully developed System would safely destroy chemical warfare agent stockpiles onsite without having to transport these highly toxic chemicals to a remote location for processing, and although we would expect additional contracts resulting from a successful completion of the Final Testing Phase no indication has been given as to the size, if any, such procurement would entail,” said P. Peter Pascali, President and CEO of PyroGenesis. “The fact that our System is in the Final Testing Phase reflects the significant advances that we, at PyroGenesis, have achieved, and which we expect to continue to achieve in the area of defense and chemical warfare agent destruction. This only further solidifies our position within the US military as being the ‘go-to’ supplier of plasma-based solutions.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc. is the world leader in the design, development, manufacture and commercialization of advanced plasma processes. PyroGenesis provides engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Its core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Its operations are ISO 9001:2008 certified, and have been ISO certified since 1997. PyroGenesis is a publicly-traded Canadian company on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace (Ticker Symbol: PYRNF). For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

Rodayna Kafal
VP, Investor Relations and Communications
(514) 937-0002
ir@pyrogenesis.com or rkafal@pyrogenesis.com
www.pyrogenesis.com

Namaste Announces Record Breaking Sales of C$1.34M Representing 21.8% Month-On-Month Increase $N.ca

Posted by AGORACOM-JC at 8:49 AM on Monday, July 10th, 2017

Nlogo

  • Achieved record monthly sales and traffic for the month of June
  • Total unaudited sales as reported by the Company were C$1,349,545 in June 2017
  • Compared to C$1,108,034 in May 2017, a 21.8% increase.

VANCOUVER, British Columbia, July 10, 2017 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has achieved record monthly sales and traffic for the month of June. The total unaudited sales as reported by the Company (including shipping revenues and after discounts and refunds) were C$1,349,545 in June 2017 compared to C$1,108,034 in May 2017, a 21.8% increase.

The month-on-month increase in revenue was achieved across the large network of sites operated by Namaste which all showed higher conversion rates. The increase in revenue is particularly pleasing as typically revenue is soft during the summer months. Namaste Vapes and Everyonedoesit showed good progress in conversion rates and average order value which were drivers of revenue growth. Australian Vaporizers benefited from an already high conversion rate which increased to 4.5% for the month.

The table below displays a revenue breakdown for Namaste’s various sales channels.

Revenues – June 2017 (C$)
Channels   6,942
Distribution Goods   143,437
Dropshipping   18,972
EDIT   191,500
Green Vapes   17,273
Namaste   547,459
Australian Vaporizers   423,961
Total revenues     1,349,545
Below are gross sales of the major sites operated by the Company. Revenues below do not include shipping revenues and are before discounts and refunds.
Selected operating data e-Commerce June 2017 in C$    
  traffic conversion orders  basket price  gross revenues
Namaste 94,139 1.96 % 1,845 $   278 $   513,827
Australian Vaporizers 45,040 4.50 % 2,026 $   182 $   367,766
EDIT 247,717 0.87 % 2,148 $   94 $   201,134
GreenVapes 3,479 1.47 % 51 $   303 $   15,469
Total   390,375 1.55 %   6,070 $    181 $    1,098,195

Namaste has implemented proprietary machine learning algorithms on several of its major sites that adjust website content and product listings ‘on-the-fly’ based on user behavior. These sites have seen substantial increases in conversion rates as a result and Namaste plans on launching the same technology throughout their platform.

At the end of June the Company granted 1,725,000 options to staff and consultants. The options will vest quarterly over a period of two years and are exercisable for five years at an exercise price of $0.25.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We’re very excited to see amazing results in June sales due to of all the hard work from our management team in implementing innovative strategies to increase sales organically. The implementation of machine learning to our platform has had immediate positive results. We expect to see similar results once this technology is launched throughout our platform. We look forward to continued growth as well as expansion into new markets and product categories.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Contact:
Sean Dollinger
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastevapes.com

FEATURE: Grizzly (GZD-TSX-V) – More than 9M oz of gold produced or as resources nearby $GZD.ca

Posted by AGORACOM-JC at 12:13 PM on Wednesday, July 5th, 2017

Gzdnew

WHY GRIZZLY DISCOVERIES?

  • World class gold and base metal deposits in British Columbia; and diamonds in Alberta.
  • More than 9 million oz Au produced or as resources in a radius of less than 70KM to Greenwood project
  • Holds, or has an interest in, metallic and industrial mineral permits for potash totalling more than 364,000 acres along the Alberta-Saskatchewan border
  • Four precious-base metal properties in British Columbia totalling over 235,000 acres. Grizzly also currently holds more than 231,000 acres in diamond properties, which host diamondiferous kimberlites in the Buffalo Head Hills and Birch Mountains of Alberta
  • Portions of Grizzly’s Greenwood Project being explored by Kinross through option agreement

EXPLORATION HIGHLIGHTS

  • Drillholes with up to 31.1% K2O results from assays on recent Grizzly drill program
  • Historic Unity Potash Mine 45 km east of existing GZD lands
  • Agrium Vanscory Potash Mine 200 km east of GZD lands
  • Significant Potash in drill core or indicated by gamma logs at depths ranging from 1,060m to 1,675m
  • Temperatures at those depths range from about 50oC to 75oC. Optimal temperature for solution mining is approximately 75oC.

POTASH DEMAND AND GROWTH

  • According to industry estimates, Canada has Potash resources of 7.3 billion tonnes – roughly 52% of the world’s supply.
  • Currently 11 mines in Saskatchewan produce the majority of Canada’s 35% contribution to the world’s annual production.
  • The arable land per person in the world is declining, and weather patterns are becoming more volatile and extreme, fuelling demand for Potash which increases the yield per acre approximately 40%.

BC PRECIOUS METALS

Greenwood Gold District

Portions of Grizzly’s Greenwood Project being explored by Kinross is 100% owned by Grizzly Discoveries Inc. and includes 131 claims that form a contiguous package totaling approximately 27,346 hectares, representing approximately one third of Grizzly’s land holdings at Greenwood. Under the terms of a September 2015 agreement, KG Exploration (Canada) Inc. can earn a 75% interest on the optioned land pursuant to an Option Agreement with Grizzly on portions of its land holdings in southeastern British Columbia by incurring US$3 million in exploration expenditures over a 5 year period. By the second anniversary of the agreement, 750 metres of diamond drilling must be completed along with US$750,000 in expenditures by September 23, 2017.

ALBERTA DIAMONDS

  • Following 12 drill holes, 3 new diamond bearing kimberlites were discovered in 2008 at the Buffalo Head Hills property.
  • Grizzly has more than 200,000 acres surrounding Diamondex & Shore Gold in the Buffalo Head Hills.
  • Two kimberlite pipes look very promising and need bulk sampling which is being planned for future dates due to Grizzly’s current potash focus.
  • Land rights are valid for 2 to 5 years based on existing development work done on properties by Grizzly.

Buffalo Head Hills Diamond Property, Alberta
A Renewed Interest in diamonds

Renewed interest in diamond exploration during 2015 and 2016 has prompted re-evaluation of Grizzly’s Buffalo Head Hills Diamond Project in north-central Alberta, which is located approximately 330 kilometres northwest of Edmonton and is easily accessed during summer and winter by a large network of roads and cutlines. Based upon an internal review of all data, the Company has staked additional permits of highly prospective lands for diamond-bearing kimberlites in the Buffalo Head Hills area. Grizzly’s total land position includes 11 permits that encompass approximately 220,000 acres.

Check Out Our Recent Fact Sheet

12 MONTH STOCK CHART

Great Atlantic Commences Excavator Trenching Program Golden Promise Gold Property in Central Newfoundland

Posted by Eric at 10:40 AM on Wednesday, July 5th, 2017

Vancouver, British Columbia (FSCwire) – GREAT ATLANTIC RESOURCES CORP. (TSXV.GR) (the “Company” or “Great Atlantic”) is pleased to announce it has commenced an excavator trenching program at its Golden Promise Gold Property in central Newfoundland. The current trenching program is part of a budgeted 2017 $700,000 exploration program on the property. Trenching is being conducted in the northern region of the property in an area of reported gold bearing quartz veins. The Golden Promise Gold Property was recently expanded to the current approximate 16,500 hectares.

 

To view the graphic in its original size, please click here

 

The Golden Promise Property hosts multiple gold-bearing quartz veins and gold-bearing float boulders. The majority of the historic work has been conducted at the Jaclyn Main Zone in the northern region of the property.

 

The current trenching program is being conducted in the area of three gold bearing quartz vein zones referred to as the Jaclyn Main, Jaclyn North and Jaclyn South.

 

To view the graphic in its original size, please click here

 

Trenches will be excavated in the east region of the Jaclyn Main Zone, east of a 2010 bulk sample trench. A National Instrument (NI) 43-101 compliant inferred resource of 921,000 tonnes at an average grade of 3.02 g/t Au (89,500 ounces contained gold) was reported in 2008 for the Jaclyn Main Zone. Gold recovery from a 2,241 tonne bulk sample collected in 2010 at the Jaclyn Main Zone was reported to average 4.47 g/t Au. The average tails grade for the sample was reported to be 1.12 g/t Au. A “back-calculated head grade of 5.59 g/t Au” was reported for the bulk sample. The Jaclyn Main Zone has been reportedly traced for a strike length of approximately 800 meters (northeast to east striking) through trenching and diamond drilling to approximately 420 meters vertical depth.

 

Trenches will be excavated at the Jaclyn North Zone east of historic trenches and diamond drill holes along the projected strike of the reported gold bearing veins. The Jaclyn North Zone is reported approximately 250 metres north of the Jaclyn Main Zone. The northeast striking Jaclyn North Zone has been reportedly traced by diamond drilling (13 holes) for approximately 450 meters and locally to a vertical depth of 175 meters.  The zone is reported to contain 3 quartz veined sub-zones. Reported drill intersections include (core length):

 

  • GP03-32:                                         12.13 g/t Au / 0.35m & 12.30 g/t Au / 0.30m

 

  • GP07-76 (Upper Sub-zone):      11.28 g/t Au / 0.30m

 

  • GP06-51 (Middle Sub-zone):     5.24 g/t Au / 1.70

 

  • GP06-47 (Lower Sub-zone):      15.23 g/t Au / 0.30m

 

 

To view the graphic in its original size, please click here

South End of Trench 1 at the Jaclyn North Zone

 

Trenches will also be excavated at the Jaclyn South Zone east-northeast of historic diamond drill holes and trenches along the projected strike of the reported gold bearing veins. The Jaclyn South Zone is reported approximately 300 meters south of the Jaclyn Main Zone consists of two sub-parallel quartz veins, one of which is reported to have been traced approximately 200 metres along strike. Previous diamond drilling in this zone consisted of four holes.  The best reported drill hole intersection was in hole GP03-31 (44.59 g/t Au / 0.30 metre core length).

 

During May and early June, the Company collected rock and soil samples in multiple additional areas within the property. These included quartz float samples in the area of planned trenches at the Jaclyn North and Jaclyn South Zones. Analyses are pending for these samples.

 

 

To view the graphic in its original size, please click here

Quartz vein rubble in lower till in Trench 1 (Jaclyn North Zone)

 

 

To view the graphic in its original size, please click here

Quartz veins in meta-sediment bedrock in Jaclyn North Zone Trench 1

 

The 2008 NI 43-101 Technical Report states the style of veining, mineralization, alteration, host rock and tectonism at Golden Promise most closely resembles other turbidite-hosted (or slate belt) gold deposits throughout the world.

 

Access is excellent with a paved provincial highway transecting the property. The property is located near the town of Badger and approximately 50 kilometres northeast of the Valentine Lake Property of Marathon Gold Corp.

 

Readers are warned that historical records referred to in this News Release have been examined but not verified by a qualified person. Further work is required to verify that historical assays referred to in this News Release are accurate.

 

David Martin, P.Geo., a Qualified Person as defined by NI 43-101, is responsible for the technical information contained in this News Release.

 

Great Atlantic is also pleased to announce that is has closed the non-brokered private placement previously announced on May 30 and June 20, 2017 for gross proceeds of $1,0000,000. The units of the financing will be comprised of one common share at a price of $0.10 and a full share purchase warrant, which may be exercised for a period of five years at a price of $0.125 per share. The term of the warrants may be accelerated in the event that the issuer’s shares trade at or above a price of $0.15 cents per share for a period of 10 consecutive days. In such case of accelerated warrants, the issuer may give notice, in writing or by way of news release, to the subscribers that the warrants will expire 30 days from the date of providing such notice. The Company announces October 10, 2017 as the hold period expiry date for the first tranche totaling 4,350,000 shares and October 15, 2017 for the second tranche totaling 2,325,000 shares and October 27, 2017 for the final tranche totaling 3,325,000 shares of  this private placement

 

 

About Great Atlantic Resources Corp.: Great Atlantic Resources Corp. is a Canadian exploration company focused on the discovery and development of mineral assets in the resource-rich and sovereign risk-free realm of Atlantic Canada, one of the number one mining regions of the world. Great Atlantic is currently surging forward building the company utilizing a Project Generation model, with a special focus on the most critical elements on the planet that are prominent in Atlantic Canada, Antimony, Tungsten and Gold.

 

On Behalf of the board of directors

 

“Lorne Mann

 

This press release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address future exploration drilling, exploration activities and events or developments that the Company expects, are forward looking statements. Although the Company believes the expectations expressed in such forward-looking statements are

based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include exploitation and exploration successes, continued availability of financing, and general economic, market or business conditions.

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

 

Great Atlantic Resource Corp

888 Dunsmuir Street – Suite 888, Vancouver, B.C., V6C 3K4

 

To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/greatatlantic07052017.pdf

Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals $TBP.ca

Posted by AGORACOM-JC at 9:05 AM on Wednesday, July 5th, 2017

Tbp large

  • Strengthened its position on bringing marijuana to patients in the form of a prescription drug
  • Has become a world leader in the field of cannabis drug development and its PPP001 dried cannabis drug was covered in the Global Pain Management Drugs Market analysis report published by Azoth Analytics in May 2017

OTTAWA, ONTARIO–(July 5, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has strengthened its position on bringing marijuana to patients in the form of a prescription drug. Tetra has become a world leader in the field of cannabis drug development and its PPP001 dried cannabis drug was covered in the Global Pain Management Drugs Market analysis report published by Azoth Analytics in May 2017. According to this report, Tetra is the only company developing dried marijuana as a drug.

One in five Canadians will live with pain in their lifetime and one in two will be affected by cancer. Canadian courts have ruled in favor of patients wanting access to marijuana for relief. In response to these decisions, the Canadian government has implemented the Access to Cannabis for Medical Purposes Regulations (ACMPR) to help bring marijuana to patients. Canada’s Prime Minister has been very favorable in bringing marijuana to patients but it will be up to corporations to step in and adhere to the Canadian Food and Drug regulations to bring marijuana medications to patients. Tetra is a world leader in the drug development field of cannabis-based medications and is paving the road to become the first company to commercialize a dried marijuana product as a drug in North America.

“Canadian’s are entitled to access to marijuana to treat their pain or its co-morbidities. It is not a question of social standing or a judgement if the act of ‘smoking’ is acceptable for patients. It is a fundamental right to have access to a botanical drug that can effectively allow patients to have a better quality of life,” commented Dr. Guy Chamberland, CSO of Tetra Bio-Pharma. “There is sufficient evidence suggesting that smoking marijuana is an adequate medication to help relieve pain and improve a patient’s well-being. Both of these are important aspects to offering effective therapies to patients. The challenge has been addressing quality and safety issues to meet the standards of a drug.”

Over the years our society has inherited an image that ‘smoking’ or ‘vaporizing’ is not associated with a healthy approach to health care. According to the expert committee on the Health Effects of Marijuana (National Academies Press, 2017), ‘smoking cannabis does not increase the risk for certain cancers (i.e., lung, head and neck)’. In addition, cancer patients typically consume an amount of dried marijuana per day, in dry weight, that is less than 1 tobacco cigarette, without the paper, per day. The significantly reduced amount of smoke per day is one of the explanations supporting that smoking marijuana does not increase the risk for these cancers. That said, these are effective routes of delivering a complex botanical medication. “Society has to focus on caring for all patients living with pain not just those that want a different dosage form,” commented Dr. Chamberland. He added, “In fact our challenge is to characterize the safety and efficacy of this therapy, ensure lot-to-lot quality, provide adequate risk information to health professionals, demonstrate the safety and efficacy so that physicians can adequately assess the potential efficacy and safety for their patient, and actively pursue more tolerable dosage forms to offer these innovative cannabis therapies to patients. In the end, a patient’s desire to smoke marijuana for relief has to be defended by Canadian courts and politicians. We live in a democratic society and we have to care for everyone.”

“Tetra undertook the development of PPP001 as a first prescription marijuana drug. The company is preparing its phase 3 trial in cancer patients and will assess the safety and efficacy using both the titanium pipe and vaporizer delivery systems. From Day 1, Tetra was dedicated to characterizing the safety and tolerability of consuming medical marijuana by smoking. Tetra also adopted the firm position of working transparently with regulators because the corporation believed it is important to bring marijuana, as traditionally used, to patients. Tetra will continue to work with provincial and federal governments, including physician and pharmacist professional corporations, to help address issues associated with the development and commercialization of a first prescription medical marijuana drug.”

“Tetra already works closely with Health Canada through the regulatory processes in place for the development of drugs and controlled substances,” commented Dr. Chamberland. He added that, “Tetra was working closely with the province of New Brunswick whom from Day 1 was very active in preparing for the eventual legalization of marijuana in Canada. Tetra is working with physician and pharmacist professional associations/corporations and will be working closely with these health professionals as the company prepares for its Phase 3 trial and the eventual commercialization of the first dried marijuana drug.”

“Tetra has performed safety, pharmacokinetic and cognitive function studies in healthy volunteers. The corporation has characterized the safety of consuming marijuana and understands what the potential risks are to consumers and patients. This information will be made available by Tetra to Health Canada and to other government departments on request. We believe that this safety data provides a clear and accurate picture of what happens to people that smoke marijuana recreationally,” commented Dr. Chamberland. “We believe it is our responsibility to provide this information to regulators to help pave the road for the Trudeau government’s legalization.”

In addition, Tetra will use its clinical knowledge from its Phase 1 and Safety clinical studies to implement effective and secure patient care programs. This includes working with independent professional organizations to transfer its clinical risk information and ensure that these groups provide continued medical education to their health professionals. Dr. Chamberland commented, “Launching the first dried marijuana drug in Canada brings a responsibility of ensuring that all safety risks are communicated to health professionals to ensure the well-being of consumers. No body wants another fentanyl-type crisis; all we want is for patients to obtain relief and an improved quality of life when consuming marijuana that is of the same quality as any other prescription medication.”

“Tetra will be actively pursuing the development and commercialization of PPP001 to remain a world leader in the field of cannabis medicine,” commented Andre Rancourt, CEO of Tetra Bio-Pharma. “We are dedicated to working with distributors and pharmaceutical companies interested in bringing medical marijuana as a prescription drug around the world. We are focusing on bringing to patients what the Supreme Court of Canada ruled was their right: access to marijuana.”

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Excavator Program Exposes Vein over 160 Meters Multiple Showings of Visible Gold on the Gold Drop Property Historic Gold Camp Greenwood BC $GGX.ca

Posted by AGORACOM-JC at 10:32 AM on Tuesday, July 4th, 2017

  • Excavator Program Exposes Vein over 160 Meters Multiple Showings of Visible Gold
  • Trenching program has now doubled the size of exposed Vein from 80 meters as reported in the June 15th News Release to 160 Meters and it appears to continue along strike

Vancouver, British Columbia (FSCwire)GGX Gold Corp. (TSXV: GGX) (the “Company” or “GGX”) is pleased to announce its excavator trenching program has now doubled the size of exposed Vein from 80 meters as reported in the June 15th News Release to 160 Meters and it appears to continue along strike. The vein is located in the Gold Drop Southwest Zone. As well the company is continuing to channel sample the newly exposed area. The company plans to begin a drilling program shortly and has spotted the first 15 holes along the newly exposed Vein. Drill pads are being constructed and discussions have been underway with contractors.

 

To view the graphic in its original size, please click here

 

The company also would like to report that there have been multiple locations were visible Gold has been spotted in bedrock throughout the property. As such the company is currently in the process of increasing security in various locations in and around the property with Wireless cameras and fencing.

 

To view the graphic in its original size, please click here

 

To view the graphic in its original size, please click here

 

The Gold Drop property covers geologically prospective ground in the well-mineralized Greenwood Mining Division. The property hosts numerous low-sulfide, gold and silver bearing quartz veins or vein systems, four of which were previously mined (Gold Drop, North Star, Amandy and Roderick Dhu veins).

 

To view the graphic in its original size, please click here

June 2017 Trenching at Gold Drop Southwest Zone (area of historic C.O.D shaft)

 

David Martin, P.Geo., a Qualified Person as defined by NI 43-101, is responsible for the technical information contained in this News Release.

 

On Behalf of the Board of Directors,

 

Barry Brown, Director

 

604-488-3900

 

Forward Looking Information

 

This news release includes certain statements that constitute “forward-looking information” within the meaning of applicable securities law, including without limitation, the Company’s information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the completion of the proposed transactions. Forward-looking statements address future events and conditions and are necessarily based upon a number of estimates and assumptions. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved), and variations of such words, and similar expressions are not statements of historical fact and may be forward-looking statements. Forward-looking statement are necessarily based upon several factors that, if untrue, could cause the actual results, performances or achievements of the Company to be materially different from future results, performances or achievements express or implied by such statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of gold and other metals, anticipated costs and the ability to achieve goals, and the Company will be able to obtain required licenses and permits. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks including that resource exploration and development is a speculative business; that environmental laws and regulations may become more onerous; that the Company may not be able to raise additional funds when necessary; fluctuating prices of metals; the possibility that future exploration, development or mining results will not be consistent with the Company’s expectations; operating hazards and risks; and competition. There can be no assurance that economic resources will be discovered or developed at the Gold Drop Property. Accordingly, actual results may differ materially from those currently anticipated in such statements. Factors that could cause actual results to differ materially from those in forward looking statements include continued availability of capital and financing and general economic, market or business conditions, the loss of key directors, employees, advisors or consultants, equipment failures, litigation, competition, fees charged by service providers and failure of counterparties to perform their contractual obligations. Investors are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. The forward-looking statements included in this news release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation.

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.